Cell Death and Disease Submission Process

This page was built from the Cell Death & Disease guide to authors, editorial-process page, data-availability policy, journal-information metrics, Springer Nature submission-status support documentation, and Manusights pre-submission analysis of Cell Death & Disease, Cell Death & Differentiation, Cell Death Discovery, Oncogene, Cancer Letters, Molecular Therapy, and adjacent disease-mechanism manuscripts. Last reviewed: July 17, 2026.

Official source facts checked in this pass include single-anonymized peer review, Article specifications, cover-letter requirements, reproducibility requirements, editorial-process steps, post-acceptance processing, and Springer Nature Data Policy Type 3.

Key limits checked: 300-word unstructured abstract, 3,500-word main-text limit, 6 to 8 tables/figures, and 80 references for Articles. Verify the current Editor-in-Chief on the journal's editorial-team page before quoting any name in a cover letter. That editorial-board context still matters because the process is read by cell-death, immunity, cancer, neuroscience, and experimental-medicine specialists, not by a generic biomedical intake team.

Recent Cell Death & Disease article records checked while validating the process show the disease-mechanism breadth authors should expect reviewers to understand: 10.1038/s41419-026-08791-1 for microglia rewiring in Alzheimer disease, 10.1038/s41419-026-08436-3 for apoptosis recovery and mitophagy in photoreceptors, and 10.1038/s41419-026-08496-5 for autophagy suppression in breast-cancer therapy resistance.

The process is deciding whether the paper is a disease-linked cell-death contribution, not merely a competent cell-biology manuscript.

The editor is usually asking:

• Does the manuscript connect apoptosis, autophagy, necroptosis, ferroptosis, pyroptosis, senescence, mitochondrial death, immune-cell death, or cancer metabolism to a disease-relevant mechanism?
• Does the model fit the disease claim: patient samples, animal model, organoid, primary cells, perturbation, rescue, dose, time course, or clinically interpretable dataset?
• Does the manuscript offer enough conceptual advance for Cell Death & Disease rather than a specialty disease journal, a basic cell-death journal, or a lower-selectivity broad venue?
• Are ethics, competing interests, image integrity, raw data, data availability, and reproducibility details credible enough for review?
• Can reviewers evaluate the methods, analysis, interpretation, and disease relevance without guessing which figure carries the claim?

This is why the page is distinct from the submission guide. The guide says what to prepare. This page explains how that package is screened after upload.

Do not submit until the package can survive both administrative checks and the first editorial read.

If the first editorial read cannot see the disease mechanism by the end of the abstract and first results section, the process is already risky.

Cell Death & Disease submissions go through the journal's online submission system. After submission, the manuscript receives a tracking number, and authors can monitor status through Springer Nature's author-facing systems.

Before confirming upload, check:

• corresponding-author information, affiliations, and author order;
• article type and word/figure/reference constraints;
• cover letter with originality, journal-fit, competing-interest, and prior-review disclosure where applicable;
• ethics approvals, consent language, tumour-burden details, and animal/human-study statements;
• data availability statement and repository/accession details;
• original image files and source data for key figures;
• suggested independent reviewers and conflict-of-interest exclusions;
• file naming, figure order, supplementary files, tables, and clean PDF generation;
• AI/LLM disclosure if any writing or analysis support was used.

The portal may accept an incomplete-looking scientific argument. The editor will not.

The initial quality check is an administrative and process-readiness gate. Springer Nature describes this stage as including checks on authorship, competing interests, ethics approval, and plagiarism. Cell Death & Disease's editorial-process page also says the editorial office checks that the paper is formatted correctly.

For Cell Death & Disease, quality-check friction often appears around:

• missing or vague ethics approvals;
• incomplete competing-interest statements;
• data availability language that does not match the figures;
• image-source material that is not organized;
• word, figure, or reference-limit mismatch;
• cover letter missing journal-fit explanation;
• disclosure gaps around previous consideration by another journal;
• article-type mismatch.

Fixing these after upload costs time and gives the editor a weaker first impression.

Once the paper clears initial checks, it is assigned to an editor. The editor decides whether the manuscript is within the journal's remit and whether it should be sent for external review.

Papers that seem least likely to meet editorial criteria may be rejected promptly without external review. That is a process feature, not an anomaly.

Cell Death & Disease identifies its peer-review model as single anonymized: reviewers are not identified to authors unless a referee requests it, review information is not published, and the reviewer interacts with the Associate Editor.

Manuscripts sent out for peer review are evaluated by at least one independent reviewer, often two or more. The journal says reviewers are given 14 days from acceptance to submit reports. In practice, elapsed time can be longer because reviewer invitation, refusal, replacement, editor synthesis, and re-review add variance.

Reviewers usually focus on:

• whether the disease model supports the stated claim;
• whether the cell-death mechanism is causally tested rather than descriptively associated;
• whether image data, flow cytometry, microscopy, tumour-growth, western blot, sequencing, or patient-data material is interpretable;
• whether statistics and controls match the biological question;
• whether translational language is proportional to the evidence;
• whether the work belongs in Cell Death & Disease rather than a sibling or specialty venue.

If the paper is sent for review, the process risk shifts from "does an editor see journal fit?" to "can reviewers verify the disease mechanism?"

This guide tells you what Cell Death & Disease editors look for in the process; the review tells you whether YOUR paper passes that process before upload. The reviewer-count expectation should stay flexible: the journal says externally reviewed manuscripts are evaluated by at least one independent reviewer and often two or more, while the practical review team may need expertise across cell-death mechanism, disease model, imaging, omics, statistics, ethics, and translational interpretation. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

The journal-specific peer-review feature is single-blind peer review, described by the journal's current terminology as single-anonymized peer review. Authors know the journal and editorial route, but referees are not identified to authors unless the referee requests it. That means the manuscript should not rely on author reputation or lab context to explain the disease mechanism. The disease claim, data package, and model logic need to stand inside the submitted file.

The official editorial-process page lists these outcomes:

For revision, authors upload a rebuttal letter, marked-up manuscript, and clean manuscript. For resubmission after rejection with resubmit option, the updated manuscript is submitted as a new manuscript with a cover letter explaining point-by-point changes.

The journal's current metrics list 7 median days to first editorial decision and 192 median days from submission to acceptance. Those metrics are useful, but they do not mean every reviewed paper receives a full peer-review decision in a week. A very fast first decision is often editorial triage. A review-routed manuscript can move more slowly because reviewer recruitment and report completion dominate the timeline.

AIO-citable timing range: use 7 days as the median first-editorial-decision benchmark, 6 to 12 weeks as a practical reviewed-manuscript decision window for ordinary cases, and 192 days as the current median submission-to-acceptance benchmark; complex or delayed edge cases extend when reviewer recruitment is slow, image/data questions require clarification, or major revision triggers re-review.

Springer Nature's submission-status guidance says corresponding or submitting authors can track the article online and see whether action is required.

Acceptance does not end the process. After acceptance, the corresponding author completes the open-access License to Publish and APC/payment forms through online portals. The accepted manuscript may publish as an Article in Press before final version-of-record processing. Proof corrections are handled through Springer Nature's e-proofing system, and the journal says proofs should be returned within 48 hours.

Prepare these before acceptance if the paper is likely to move forward:

• final affiliation and funding details;
• APC funding, waiver, or institutional-coverage plan;
• corresponding-author availability for forms and proofs;
• figure-source files and production-ready tables;
• author-name, ORCID, affiliation, and contribution checks;
• press-release coordination only after production guidance is clear.

Late proof or license handling creates avoidable publication delay.

In our pre-submission review work for Cell Death & Disease and adjacent CDD Press routes, the most useful process signals appear before upload. The editor's first read is testing whether the manuscript's strongest biological claim is also the journal-fit claim.

This is also where the page's information gain sits. Official pages describe the workflow; they do not tell an author which manuscript components change the odds of passing editor triage. In our work, the process outcome usually turns less on formatting and more on whether the paper makes a disease-mechanism decision visible before reviewers have to infer it. The useful artifact is therefore not "submit and wait." It is a route decision: submit now, repair the mechanism package, or redirect to a sibling journal before the tracking number is created.

We see the same editorial triage pattern across disease-mechanism drafts: editors specifically look for the figure or method that converts a cell-death observation into a disease claim. Editorial policy states the review path only starts after the manuscript clears initial quality and editor assignment, so Manusights submission analysis treats the first process question as a manuscript-specific fit test rather than a portal-completion task.

Cell-death marker story without disease mechanism. The paper shows apoptosis, ferroptosis, necroptosis, autophagy, senescence, mitochondrial dysfunction, or immune-cell death markers, but the disease consequence is implied rather than tested. This can pass a format check and still fail editor triage.

Check whether your Cell Death & Disease submission proves disease mechanism →

Functional evidence does not match translational language. The manuscript claims therapeutic, diagnostic, biomarker, or disease-stage importance, but the figures support only a narrower cell or pathway observation. Editors and reviewers usually read that as overclaiming.

Check whether your functional evidence supports the claimed disease relevance →

Data and image package is not process-ready. Original blots, microscopy, IHC, ICC, flow cytometry, sequencing, tumour-growth, or patient-data support is hard to inspect. For this journal, the data package is not a back-office detail; it affects whether review can be fair and efficient.

Check whether your data and image package is ready for review →

Cover letter does not explain why this is not Cell Death & Differentiation or Cell Death Discovery. The CDD Press family creates a routing test. The letter should make disease focus, mechanism, model, and audience explicit. If the route is wrong, transfer may be cleaner than forcing the wrong journal.

Check whether Cell Death & Disease is the right CDD Press route →

Run the same checks the process will run later, but while you can still fix the package.

If two or more of these checks fail, the next step is not submission. It is package repair.

For this process page, the reviewer count is less important than the editorial route: Cell Death & Disease says externally reviewed manuscripts are evaluated by at least one independent reviewer and often two or more, but the first conversion-critical question is whether an editor will send the manuscript out at all.

• Cell Death and Disease submission guide
• Cell Death and Disease journal profile
• Rejected from Cell Death and Disease? Where to submit next
• Cell Death and Differentiation submission guide
• Rejected from Cell Death and Differentiation: where next?

Before upload, run a Cell Death and Disease submission-process review. It checks whether the process will see a coherent disease-mechanism claim, not just a complete file set.